How confidential trial negotiations and agreements between the food and drug administration and sponsors marginalize local institutional review boards, and what to do about it

American Journal of Bioethics 6 (3):22 – 24 (2006)
  Copy   BIBTEX

Abstract

This Article does not have an abstract

Categories

Keywords

Reprint years

DOI

10.1080/15265160600685663

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 93,990

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.Yashashri C. Shetty & Aafreen A. Saiyed - 2015 - Journal of Medical Ethics 41 (5):398-403.
Institutional review boards lack the moral legitimacy to reinterpret subpart D.Robert M. Nelson - 2008 - American Journal of Bioethics 8 (4):37 – 39.
Moral Wrongs, Epistemic Wrongs, and the FDA.Jack Harris - 2022 - American Journal of Bioethics 22 (10):34-37.
Limitations on the Capability of the FDA to Advise.Aaron S. Kesselheim & Leah Z. Rand - 2022 - American Journal of Bioethics 22 (10):15-17.
Stepping Up or Stepping Back: FDA Roles in Producing and Shaping Knowledge of Pediatric Covid-19 Vaccines.Sophia Bessias & Elizabeth Lanphier - 2022 - American Journal of Bioethics 22 (10):26-28.
Opioid Treatment Agreements Are the Answer. What Is the Question?Scott Burris & Evan Anderson - 2010 - American Journal of Bioethics 10 (11):15-17.
Response to Open Peer Commentaries on “An Open Letter to Institutional Review Boards Considering Northfield Laboratories' PolyHeme® Trial ”: The Emergency Exception and Unproven/Unsatisfactory Treatment.Ken Kipnis, Nancy M. P. King & Robert M. Nelson - 2006 - American Journal of Bioethics 6 (3):W49-W50.
Review of Sonia Shah. The body hunters: How the drug industry tests its products on the world's poorest patients. [REVIEW]Jennifer S. Bard - 2008 - American Journal of Bioethics 8 (2):52 – 53.
Response to Open Peer Commentaries on “An Open Letter to Institutional Review Boards Considering Northfield Laboratories' PolyHeme® Trial”: The Emergency Exception and Unproven/unsatisfactory Treatment.Ken Kipnis, Nancy M. P. King & Robert M. Nelson - 2006 - American Journal of Bioethics 6 (3):W49-W50.
What to do about the mere potential for disabilities.D. Micah Hester - 2001 - American Journal of Bioethics 1 (3):1 – 2.

Analytics

Added to PP
2009-01-28

Downloads
9 (#1,270,032)

6 months
2 (#1,448,208)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Add more citations

References found in this work

Add more references